Ghanaian pharmaceutical firm Atlantic Lifesciences has begun local production and distribution of anti-snake venom, marking what it describes as a major milestone in strengthening the country’s healthcare capacity.
The announcement was made in a statement published on the official Facebook page of the German Embassy Accra.
Jafar Seidu Tonzua, Head of International Business at Atlantic Lifesciences, described the development as a significant achievement for the company.
“Producing our first biological product, which is the anti-snake vaccine, and bringing it to the market is a major milestone and a moment of immense pride for our team,” he said.
According to the statement, local production of the anti-snake venom is expected to reduce Ghana’s reliance on imports while boosting domestic pharmaceutical manufacturing capacity.
The initiative is supported by Germany, with co-financing from the European Union, as part of efforts to strengthen Ghana’s healthcare infrastructure and position the country as a regional hub for vaccine production.
The programme forms part of the Team Europe Initiative MAV+ and is co-funded by the European Union and the German Federal Ministry for Economic Cooperation and Development.
The embassy noted that the project is being driven by a relatively young team, with an average age of 35, and aims not only to improve access to essential medicines but also to promote innovation, job creation and economic empowerment.
Snakebite remains a public health concern in parts of Ghana, particularly in rural communities, where timely access to anti-venom treatment can be limited.
Source :www.kumasimail.com
